Table 2.
Clinical and paraclinical characteristics of patients according to their outcomes: critical evolution (ICU admission or death before 28 days after diagnosis) or non-critical evolution
| Characteristics | All patients (n = 122) | Non-critical evolution (n = 77) | Critical evolution (n = 45) | P-value |
|---|---|---|---|---|
| Initial symptoms | ||||
| No, n (%) | 10 (8) | 9 (12) | 1 (2) | 0.09 |
| Yes, n (%) | 112 (92) | 68 (88) | 44 (98) | |
| Flu-like symptoms, n (% of symptomatic) | 34 (30) | 23 (34) | 11 (25) | 0.33 |
| Fever, n (% of symptomatic) | 81 (72) | 53 (78) | 28 (64) | 0.10 |
| Cough, n (% of symptomatic) | 77 (69) | 49 (72) | 28 (64) | 0.35 |
| Dyspnoea, n (% of symptomatic) | 47 (42) | 21(31) | 26 (59) | 0.003 |
| Digestive, n (% of symptomatic) | 21 (19) | 14 (21) | 7 (16) | 0.54 |
| Anosmia and/or ageusia, n (% of symptomatic) | 5 (4) | 4 (6) | 1 (2) | 0.37 |
| SBP, median of symptomatic (IQR), mmHg | 129 (111–190) | 130 (113–144) | 134 (106–141) | 0.42 |
| SBP, median of symptomatic (IQR), mmHg | 68 (60–79) | 70 (60–78) | 63 (57–79) | 0.13 |
| Temperature, median of symptomatic (IQR), °C | 37.6 (36.8–38.3) | 37.7 (36.6–38.3) | 37.7 (36.8–38.5) | 0.90 |
| Heart rate, median of symptomatic (IQR), b.p.m. | 78 (70–90) | 76 (65–88) | 83 (72–94) | 0.05 |
| Respiratory rate, median of symptomatic (IQR), c.p.m. | 21 (16–25) | 20 (16–25) | 20 (16–26) | 0.67 |
| Oxygen therapy on diagnosis, n (% of all patients) | 55 (45) | 25 (32) | 30 (67) | <0.001 |
| Oxygen flow rate on diagnosis, median (IQR), L/min | 2 (1–4) | 2 (1–3) | 3 (2–4) | 0.04 |
| Laboratory variable on admission, median (IQR) | ||||
| Haemoglobin, g/dL | 10.7 (9.7–11.6) | 10.8 (9.8–11.8) | 10.3 (9.3–11.6) | 0.23 |
| Platelets, G/L | 166 (124–226) | 166 (123–228) | 167 (129–220) | 0.60 |
| Leucocytes, G/L | 4.9 (3.7–7.3) | 4.6 (3.7–6.4) | 5.9 (4.1–8.7) | 0.10 |
| Neutrophils, G/L | 3.6 (2.6–5.5) | 3.2 (2.5–4.7) | 4.7 (3.0–7.2) | 0.03 |
| Lymphocytes, G/L | 0.78 (0.46–1.09) | 0.90 (0.61–1.18) | 0.60 (0.40–0.86) | <0.001 |
| Eosinophil, G/L | 0.03 (0.00–0.10) | 0.04 (0.00–0.11) | 0.01 (0.00–0.10) | 0.30 |
| Monocytes, G/L | 0.42 (0.29–0.70) | 0.40 (0.25–0.60) | 0.50 (0.30–0.80) | 0.09 |
| CRP, mg/L | 47.5 (15.6–95.1) | 25.4 (11.6–75.0) | 68.5 (32.1–132.0) | 0.006 |
| Albumin, g/L | 34.5 (30.0–37.5) | 35.0 (31.0–38.6) | 32.4 (29.9–37.0) | 0.19 |
| LDH, UI/L | 282 (217–394) | 252 (211–388) | 305 (265–421) | 0.42 |
| Ferritin, µg/L | 771 (469–1609) | 754 (446–1514) | 958 (527–1937) | 0.48 |
| Fibrinogen, g/L | 5.1 (4.4–6.7) | 4.8 (4.2–5.7) | 5.9 (4.8–7.3) | 0.02 |
| D-Dimer, µg/mL | 1.43 (0.81–2.76) | 1.06 (0.66–1.63) | 2.32 (1.26–3.77) | 0.02 |
| Troponins T, ng/mL | 108 (61–192) | 92 (52–142) | 140 (98–307) | 0.43 |
| Hepatic cytolysis, n (%) | 29 (25) | 13 (18) | 16 (38) | 0.02 |
| PCR SARS-CoV-2 positive, n (%) | 113 (93) | 72 (94) | 41 (91) | 0.46 |
| Chest CT scan on admission | ||||
| Chest CT scan realized, n (%) | 89 (73) | 53 (69) | 36 (80) | 0.21 |
| Pathological, n (% of CT scan) | 71 (80) | 42 (79) | 29 (81) | 0.99 |
| Ground-glass opacity, n (% of CT scan) | 65 (92) | 39 (74) | 26 (72) | 0.99 |
| Crazy paving, n (% of CT scan) | 12 (18) | 7 (13) | 5 (14) | 0.75 |
| Consolidation, n (% of CT scan) | 29 (41) | 13 (26) | 16 (44) | 0.02 |
| Pleural effusion, n (% of CT scan) | 10 (14) | 2 (4) | 8 (22) | 0.005 |
| Lesions extension degree <50%, n (% of CT scan) | 53 (61) | 32 (60) | 21 (59) | 0.84 |
| Lesions extension degree >50%, n (% of CT scan) | 15 (17) | 8 (15) | 7 (19) | |
| Lesions extension degree not precise, n (% of CT scan) | 3 (4) | 2 (4) | 1 (3) | |
Quantitative data are expressed in median (IQR 25–75% quartile).
SBP, systolic blood pressure; G, giga.